

John C. Puente, M.D.
CCT Research
1910 S Stapley Drive, Suite 120
Mesa, AZ 85204

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 939-6696
Fax (208) 575-3169
Email: clinicaltrials@alliancesites.com

AFFILIATIONS:

Bryan LGH Medical Centers
East Campus
1600 S. 48th St.
Lincoln, NE 68506
West Campus
2300 S. 16th St.
Lincoln, NE 68502

St. Elizabeth's Regional Medical Center
555 S 70th Street
Lincoln, NE

Beatrice Community Hospital
4800 Hospital Parkway
Beatrice, NE 68310-6906

St. Mary's Hospital
1301 Grundman Blvd.
Nebraska City, NE

The Heritage at Sterling Ridge/CCT Research
1111 Sterling Ridge Drive
Omaha, NE 68144

West Omaha Family Physicians, P.C./CCT Research
17030 Lakeside Hills Plaza, Suite 130
Omaha, NE 68130

Skyline Medical Center, PC/ CCT Research
1908 N 203rd Street, Suite #2
Elkhorn, NE 68022

AFFILIATIONS (continued):

Methodist Physicians Clinic/CCT Research
350 W 23rd
Fremont, NE 68025

EDUCATION:

1996-00 M.D.
University of Nebraska Medical Center, Omaha, NE

1989-92 B.S.
Business Administration in Finance, Creighton University, Omaha, NE

LICENSURE:

Nebraska Medical License #22773

INTERNSHIPS AND RESIDENCIES:

2000-04 Chief Resident Neurology
University of Nebraska Medical Center, Omaha, NE

CERTIFICATION:

Board Certified Neurology, State of Nebraska
ACLS Certification
NIH Stroke Scale Certification

PROFESSIONAL EXPERIENCE:

Principal Investigator, 2018 – present
CCT Research, Scottsdale, AZ

Neurologist, 2016- Present
Neurology Consultants of Nebraska, P.C., Omaha, NE

Company President & Neurologist, 2013-16
Multiple Sclerosis Center of Nebraska, P.C., Lincoln, NE

Neurologist, 2011-13
Neurological and Spinal Surgery, L.L.C., Lincoln, NE

Neurologist, 2004-11
Neurology Associates, P.C., Lincoln, NE

INVESTIGATOR EXPERIENCE:

ALS • Alzheimer's Disease • Multiple Sclerosis • Neuropathic Pain • Parkinson's Disease

INVESTIGATOR EXPERIENCE:

Alzheimer's Disease

A Phase III, multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy and safety of XXX in treatment of mild to moderate Alzheimer's disease

A Phase III, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of XXX in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

A 12-Month, Open-Label Safety Study of XXX in Mild-to-moderate Alzheimer's Disease Patients

A Phase IIb, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of XXX in Mild-to-moderate Alzheimer's Disease Patients

A Phase IIa, Open-label, Multiple Dose, Safety, Pharmacokinetic and Biomarker Study of XXX in Mild-to-moderate Alzheimer's Disease Patients

A Phase III Safety and Efficacy Study of XXX in Subjects With Evidence of Early Alzheimer's Disease

ALS

A Randomized, Double-Blind, Placebo Controlled, Multicenter Study of the Safety and Efficacy of XXX in Subjects with Amyotrophic Lateral Sclerosis

Multiple Sclerosis

A Phase III, Randomized, Double-blind Efficacy and Safety Study Comparing Oral XXX to Oral XXX in Participants With Relapsing Forms of Multiple Sclerosis (RMS-1)

A Phase III XXX vs XXX Trial, a Registrational Study Evaluating Treatment in Subjects with Relapsing Multiple Sclerosis

A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient Reported Outcomes of Oral XXX (XXX) Delayed-Release Capsules in Patients with Relapsing Forms of Multiple Sclerosis After Response to XXX

INVESTIGATOR EXPERIENCE (*continued*):

A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of XXX Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

A Multicenter, Observational, Open-Label, Single-Arm Study of XXX in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with XXX: Stratify-2

Parkinson's Disease

Multicenter, Double-blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Effect of XXX on Motor Symptoms in Patients with Advanced Parkinson's Disease with Motor Fluctuations and Gastroparesis

Other Indications

A Phase II, Randomized, Double-blind, Placebo and Active Comparator-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of XXX in the Treatment of Diabetic Peripheral Neuropathic Pain

Named Protocol XXX Patient Program with XXX